Glycosmedia

Diabetes News Service

  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Insulin pumps – beyond injections

June 16th 2013

Despite advances in insulin technology and the development of different regimens including multiple daily injections (MDI), there still remain a group of patients with Type 1 diabetes who pose significant management problems. Problems include erratic blood glucose readings, unpredictable and debilitating hypoglycaemia and issues with injection sites. For this group of patients, an insulin pump is an option.

An insulin pump is a pager sized device worn continuously by the patient. It contains a reservoir of insulin which is infused continuously via a giving set inserted subcutaneously, usually into the lower abdomen. The insulin infusion is usually divided into a basal rate with boluses given at meal times. Whilst this may sound like a technological method of MDI, the increasingly sophistication means that basal and bolus rates can be programmed separately, giving a level of flexibility and accuracy greater than a subcutaneous injection. The basal rate can be changed depending on the time of day whilst the bolus can be tailored specifically to the type of food. Of course all of this requires an increased level of training and education for the patient both on how to manage the pump as well as carbohydrate counting and dietary knowledge. Usually patients need to test their blood glucose more intensively in order to adjust their insulin rate although there are an increasing number of sophisticated pumps which link to continuous glucose sensors via Bluetooth in a ‘closed loop’ system.

The majority of patients with a pump feel more empowered to self manage their blood glucose levels especially given the freedom from injections. However, others find the thought of permanently being attached to a device difficult to manage. This includes certain activities and some limitation on clothing. Furthermore, all patients will need to be able to switch to injections should any pump issues arise unexpectedly.

As expected, NICE has issued guidance (although surprisingly not updated since 2008). Currently NICE recommend insulin pumps for patients whose attempts to achieve target haemoglobin A1c (HbA1c) levels with multiple daily injections (MDIs) result in the person experiencing disabling hypoglycaemia and for patients whose HbA1c levels have remained high (that is, at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care. They are not recommended for patients with Type 2 diabetes.

Dr Mark Freeman

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsor

Sanofi Diabetes

Gold Sponsors

Novo NordiskNapp DiabetesAstraZenecaBoehringer Ingelheim LillyMSD

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Share Glycosmedia

Follow us on Twitter

My Tweets

Glycosmedia App

mobileA Glycosmedia iPhone/iPad App is available FREE from the iTunes store.


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


HONcode Standard

HONConduct783211_s2This site complies with the HONcode standard for trustworthy health information: verify here.

Copyright © 2018 Glycosmedia Partnership